Kura Oncology (NASDAQ:KURA) Downgraded by ValuEngine to “Hold”

Kura Oncology (NASDAQ:KURA) was downgraded by research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research report issued on Monday, ValuEngine reports.

Several other equities research analysts also recently commented on the stock. JMP Securities restated a “market outperform” rating and issued a $22.00 target price on shares of Kura Oncology in a research note on Thursday, September 5th. Deutsche Bank initiated coverage on shares of Kura Oncology in a research note on Thursday, July 18th. They issued a “buy” rating and a $28.00 target price on the stock. BidaskClub upgraded shares of Kura Oncology from a “strong sell” rating to a “sell” rating in a research note on Friday, October 18th. HC Wainwright restated a “buy” rating and issued a $29.00 target price on shares of Kura Oncology in a research note on Friday, August 2nd. Finally, Zacks Investment Research downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating in a research note on Tuesday, September 17th. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $27.10.

Shares of Kura Oncology stock opened at $15.10 on Monday. The firm has a market capitalization of $677.85 million, a PE ratio of -8.78 and a beta of 2.58. The company has a debt-to-equity ratio of 0.03, a current ratio of 23.50 and a quick ratio of 23.50. The company’s fifty day moving average price is $15.18 and its two-hundred day moving average price is $16.93. Kura Oncology has a 52-week low of $10.20 and a 52-week high of $21.42.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.41) by $0.03. Analysts predict that Kura Oncology will post -1.61 earnings per share for the current fiscal year.

Large investors have recently modified their holdings of the company. CVI Holdings LLC acquired a new position in Kura Oncology during the 2nd quarter worth about $1,197,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Kura Oncology by 599.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,824 shares of the company’s stock valued at $56,000 after purchasing an additional 2,420 shares during the period. Swiss National Bank lifted its position in Kura Oncology by 36.1% during the 2nd quarter. Swiss National Bank now owns 61,400 shares of the company’s stock valued at $1,209,000 after purchasing an additional 16,300 shares during the period. Fosun International Ltd lifted its position in Kura Oncology by 21.2% during the 2nd quarter. Fosun International Ltd now owns 370,958 shares of the company’s stock valued at $7,341,000 after purchasing an additional 65,000 shares during the period. Finally, Allianz Asset Management GmbH lifted its position in Kura Oncology by 38.7% during the 2nd quarter. Allianz Asset Management GmbH now owns 127,534 shares of the company’s stock valued at $2,511,000 after purchasing an additional 35,600 shares during the period. Institutional investors own 85.46% of the company’s stock.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Read More: Buy Rating

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.